2013 ACC/AHA Guideline: A guideline for the population - Without evidence from the population

Cardiovascular Drugs and Therapy

Volumn 28, Issue 3, 2014, Pages 203-204

  Myerson, Merle ^a,b   Rosenson, Robert S ^c,d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Department of Medicine   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); EDITORIAL; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CARDIOLOGY; CORONARY ARTERY DISEASE; HYPERCHOLESTEROLEMIA; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT;

AMERICAN HEART ASSOCIATION; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOLOGY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84903757393     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6513-1     Document Type: Editorial

References (7)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013.
2. Anderson TJ, Gergoire J, Hegele RA. 2012 Update of the Canadian Cardiovascular Society Guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151-67.
3. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;2175:S1-S44.
4. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six-year follow up experience. The Framingham Heart Study. Ann Intern Med. 1961;55:33-50.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). http://www.nhlbi.nih.gov
6. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. J Clin Lipidol. 2014;29-60.
7. Grundy SM, Cleeman JI, Merz NB, Brewer HB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)